Annual Accounts Receivable
$6.65 M
-$1.97 M-22.85%
September 30, 2024
Summary
- As of February 8, 2025, ENTA annual accounts receivable is $6.65 million, with the most recent change of -$1.97 million (-22.85%) on September 30, 2024.
- During the last 3 years, ENTA annual accounts receivable has fallen by -$16.93 million (-71.81%).
- ENTA annual accounts receivable is now -90.11% below its all-time high of $67.20 million, reached on September 30, 2018.
Performance
ENTA Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Receivable
$6.65 M
-$1.53 M-18.71%
September 30, 2024
Summary
- As of February 8, 2025, ENTA quarterly accounts receivable is $6.65 million, with the most recent change of -$1.53 million (-18.71%) on September 30, 2024.
- Over the past year, ENTA quarterly accounts receivable has dropped by -$1.97 million (-22.85%).
- ENTA quarterly accounts receivable is now -91.33% below its all-time high of $76.63 million, reached on December 31, 2014.
Performance
ENTA Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
ENTA Accounts Receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -22.9% | -22.9% |
| 3 y3 years | -71.8% | -71.8% |
| 5 y5 years | -87.0% | -71.8% |
ENTA Accounts Receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -71.8% | at low | -76.0% | at low |
| 5 y | 5-year | -87.0% | at low | -87.4% | at low |
| alltime | all time | -90.1% | +2446.4% | -91.3% | +2446.4% |
Enanta Pharmaceuticals Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | $6.65 M(-22.8%) | $6.65 M(-18.7%) |
| Jun 2024 | - | $8.18 M(+5.4%) |
| Mar 2024 | - | $7.76 M(-5.1%) |
| Dec 2023 | - | $8.17 M(-5.1%) |
| Sep 2023 | $8.61 M(-57.6%) | $8.61 M(-54.4%) |
| Jun 2023 | - | $18.89 M(+6.2%) |
| Mar 2023 | - | $17.80 M(-21.2%) |
| Dec 2022 | - | $22.59 M(+11.2%) |
| Sep 2022 | $20.32 M(-13.8%) | $20.32 M(+4.3%) |
| Jun 2022 | - | $19.48 M(+4.1%) |
| Mar 2022 | - | $18.72 M(-32.3%) |
| Dec 2021 | - | $27.65 M(+17.3%) |
| Sep 2021 | $23.58 M(+0.4%) | $23.58 M(+9.0%) |
| Jun 2021 | - | $21.62 M(+7.4%) |
| Mar 2021 | - | $20.13 M(-36.6%) |
| Dec 2020 | - | $31.74 M(+35.1%) |
| Sep 2020 | $23.49 M(-54.2%) | $23.49 M(+25.9%) |
| Jun 2020 | - | $18.65 M(-32.5%) |
| Mar 2020 | - | $27.62 M(-47.5%) |
| Dec 2019 | - | $52.57 M(+2.4%) |
| Sep 2019 | $51.31 M(-23.6%) | $51.31 M(+15.7%) |
| Jun 2019 | - | $44.37 M(+12.0%) |
| Mar 2019 | - | $39.63 M(-43.3%) |
| Dec 2018 | - | $69.89 M(+4.0%) |
| Sep 2018 | $67.20 M | $67.20 M(+17.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2018 | - | $57.26 M(+30.0%) |
| Mar 2018 | - | $44.05 M(+90.6%) |
| Dec 2017 | - | $23.11 M(+117.7%) |
| Sep 2017 | $10.61 M(-17.3%) | $10.61 M(+41.3%) |
| Jun 2017 | - | $7.51 M(-16.2%) |
| Mar 2017 | - | $8.96 M(-14.0%) |
| Dec 2016 | - | $10.42 M(-18.9%) |
| Sep 2016 | $12.84 M(-16.0%) | $12.84 M(-8.1%) |
| Jun 2016 | - | $13.98 M(+7.5%) |
| Mar 2016 | - | $13.00 M(-27.2%) |
| Dec 2015 | - | $17.87 M(+16.9%) |
| Sep 2015 | $15.29 M(+786.8%) | $15.29 M(+30.4%) |
| Jun 2015 | - | $11.72 M(+65.6%) |
| Mar 2015 | - | $7.08 M(-90.8%) |
| Dec 2014 | - | $76.63 M(+4344.7%) |
| Sep 2014 | $1.72 M(+113.4%) | $1.72 M(+332.1%) |
| Jun 2014 | - | $399.00 K(-60.0%) |
| Mar 2014 | - | $998.00 K(+257.7%) |
| Dec 2013 | - | $279.00 K(-65.5%) |
| Sep 2013 | $808.00 K(-23.0%) | $808.00 K(-7.8%) |
| Jun 2013 | - | $876.00 K(+30.9%) |
| Mar 2013 | - | $669.00 K(-95.3%) |
| Dec 2012 | - | $14.33 M(+1266.3%) |
| Sep 2012 | $1.05 M(+301.9%) | $1.05 M(-46.8%) |
| Jun 2012 | - | $1.97 M(+655.9%) |
| Sep 2011 | $261.00 K | $261.00 K |
FAQ
- What is Enanta Pharmaceuticals annual accounts receivable?
- What is the all time high annual accounts receivable for Enanta Pharmaceuticals?
- What is Enanta Pharmaceuticals annual accounts receivable year-on-year change?
- What is Enanta Pharmaceuticals quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Enanta Pharmaceuticals?
- What is Enanta Pharmaceuticals quarterly accounts receivable year-on-year change?
What is Enanta Pharmaceuticals annual accounts receivable?
The current annual accounts receivable of ENTA is $6.65 M
What is the all time high annual accounts receivable for Enanta Pharmaceuticals?
Enanta Pharmaceuticals all-time high annual accounts receivable is $67.20 M
What is Enanta Pharmaceuticals annual accounts receivable year-on-year change?
Over the past year, ENTA annual accounts receivable has changed by -$1.97 M (-22.85%)
What is Enanta Pharmaceuticals quarterly accounts receivable?
The current quarterly accounts receivable of ENTA is $6.65 M
What is the all time high quarterly accounts receivable for Enanta Pharmaceuticals?
Enanta Pharmaceuticals all-time high quarterly accounts receivable is $76.63 M
What is Enanta Pharmaceuticals quarterly accounts receivable year-on-year change?
Over the past year, ENTA quarterly accounts receivable has changed by -$1.97 M (-22.85%)